EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Topical calcineurin and mammalian target of rapamycin inhibitors in inflammatory dermatoses: Current challenges and nanotechnology‑based prospects (Review)

Polytimi Sidiropoulou, Martha Katsarou, Maria Sifaki, Maria Papasavva, Nikolaos Drakoulis

International Journal of Molecular Medicine · 2024

DOI: 10.3892/ijmm.2024.5409 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Medicine, 2024. Verfasst von Polytimi Sidiropoulou und 4 weiteren Autor:innen. Beteiligte Einrichtung: 1st Department of Dermatology‑Venereology, School of Medicine, National and Kapodistrian University of Athens, 'A. Sygros' Hospital for Skin and Vene…. Hauptthemen laut MEDLINE: Calcineurin Inhibitors, MTOR Inhibitors. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 147 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Topical therapy remains a critical component in the management of immune‑mediated inflammatory dermatoses such as psoriasis and atopic dermatitis. In this field, macrolactam immunomodulators, including calcineurin and mammalian target of rapamycin inhibitors, can offer steroid‑free therapeutic alternatives. Despite their potential for skin‑selective treatment compared with topical corticosteroids, the physicochemical properties of these compounds, such as high lipophilicity and large molecular size, do not meet the criteria for efficient penetration into the skin, especially with conventional topical vehicles. Thus, more sophisticated approaches are needed to address the pharmacokinetic limitations of traditional formulations. In this regard, interest has increasingly focused on nanoparticulate systems to optimize penetration kinetics and enhance the efficacy and safety of topical calcineurin and mTOR inhibitors in inflamed skin. Several types of nanovectors have been explored as topical carriers to deliver tacrolimus in both psoriatic and atopic skin, while preclinical data on nanocarrier‑based delivery of topical sirolimus in inflamed skin are also emerging. Given the promising preliminary outcomes and the complexities of drug delivery across inflamed skin, further research is required to translate these nanotherapeutics into clinical settings for inflammatory skin diseases. The present review outlined the dermatokinetic profiles of topical calcineurin and mTOR inhibitors, particularly tacrolimus, pimecrolimus and sirolimus, focusing on their penetration kinetics in psoriatic and atopic skin. It also summarizes the potential anti‑inflammatory benefits of topical sirolimus and explores novel preclinical studies investigating dermally applied nanovehicles to evaluate and optimize the skin delivery, efficacy and safety of these 'hard‑to‑formulate' macromolecules in the context of psoriasis and atopic dermatitis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Calcineurin InhibitorsMTOR InhibitorsHumansAnimalsAdministration, TopicalNanotechnologyDermatitis, AtopicNanoparticlesTacrolimusSirolimusDrug Delivery Systems

Stichwörter der Autor:innen

PI3K‑Akt‑mTORatopic dermatitisdermatopharmacokineticsnanomaterialsnanomedicine‑based drug delivery systemsnanosystemsskin absorptionskin pharmacokineticstopical calcineurin inhibitorstopical delivery

Substanzen

Calcineurin InhibitorsMTOR InhibitorsTacrolimusSirolimus

Autor:innen und Institutionen

  • 1st Department of Dermatology‑Venereology, School of Medicine, National and Kapodistrian University of Athens, 'A. Sygros' Hospital for Skin and Venereal Diseases, 16121 Athens, Greece.
  • Research Group of Clinical Pharmacology and Pharmacogenomics, Faculty of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, 15771 Athens, Greece.
  • Department of Pharmacy, School of Health Sciences, Frederick University, 1036 Nicosia, Cyprus.

Zitieren

APA

Sidiropoulou, P., Katsarou, M., Sifaki, M., Papasavva, M., & Drakoulis, N. (2024). Topical calcineurin and mammalian target of rapamycin inhibitors in inflammatory dermatoses: Current challenges and nanotechnology‑based prospects (Review). International Journal of Molecular Medicine. https://doi.org/10.3892/ijmm.2024.5409

Vancouver

Sidiropoulou P, Katsarou M, Sifaki M, Papasavva M, Drakoulis N. Topical calcineurin and mammalian target of rapamycin inhibitors in inflammatory dermatoses: Current challenges and nanotechnology‑based prospects (Review). International Journal of Molecular Medicine. 2024. doi:10.3892/ijmm.2024.5409

BibTeX
@article{Sidiropoulou2024,
  author = {Sidiropoulou, Polytimi and Katsarou, Martha and Sifaki, Maria and Papasavva, Maria and Drakoulis, Nikolaos},
  title = {Topical calcineurin and mammalian target of rapamycin inhibitors in inflammatory dermatoses: Current challenges and nanotechnology‑based prospects (Review)},
  journal = {International Journal of Molecular Medicine},
  year = {2024},
  doi = {10.3892/ijmm.2024.5409}
}
Kostenlos starten →